Warning Letter — Reliance Life Sciences Private Limited
The FDA issued a Warning Letter to Reliance Life Sciences Private Limited following an inspection by the Center for Drug Evaluation and Research (CDER). The letter identifies specific violations of current Good Manufacturing Practice (CGMP) regulations at the firm's facility.
This affects Reliance Life Sciences Private Limited, specifically their drug manufacturing operations, quality management personnel, and regulatory compliance teams.
A Warning Letter from CDER signifies that the FDA considers the observed violations to be of regulatory significance, potentially impacting the firm's ability to receive new product approvals or maintain existing supply chains. It indicates that previous responses to inspectional observations (Form FDA 483) may have been insufficient to address systemic quality concerns.
Quality units should review site-specific CGMP compliance, specifically regarding documentation practices and process controls, to ensure readiness for CDER inspections. Any identified gaps in manufacturing oversight should be addressed through documented CAPA plans.
FDA Warning Letter issued to: Reliance Life Sciences Private Limited. 08/18/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reliance-life-sciences-private-limited-730801-08182026
Open in openFDA / FDA.gov